The future of exogenous surfactant therapy

Respiratory Care

Volumn 56, Issue 9, 2011, Pages 1369-1386

  Willson, Douglas F ^a   Notter, Robert H ^b  

^a UNIVERSITY OF VIRGINIA CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; ALI; ARDS; Infant respiratory distress syndrome; Neonatal; RDS; Surfactant

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; BERACTANT; BOVACTANT; BOVINE LUNG EXTRACT SURFACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; EXOGENOUS SURFACTANT; LUCINACTANT; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; LUSUPULTIDE; PLACEBO; PORACTANT; PUMACTANT; RESPIRATORY TRACT AGENT; SURFACTANT TA; UNCLASSIFIED DRUG; DEPN 8; DRUG DERIVATIVE;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RESPONSE; EXOGENOUS SURFACTANT THERAPY; HUMAN; MECONIUM ASPIRATION; NEWBORN PERIOD; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PNEUMONIA; PULMONARY ASPIRATION; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FUNCTION; SEPSIS; SUBSTITUTION THERAPY; VIRAL BRONCHIOLITIS; ANIMAL; CHEMISTRY; CLASSIFICATION; EXTRACORPOREAL OXYGENATION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; REVIEW;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ACUTE LUNG INJURY; ANIMALS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; INFANT, NEWBORN; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 82255196405     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01306     Document Type: Article

References (212)

1. von Neergaard K. Neue auffassungen uber einen grundbegriff der atemmechanik. Dieretraktionskraft der lunge, abhangig von der oberflachenspannung in den alveolen. Z Ges Exp Med 1929;66:373-394. Article in German.
2. Pattle RE. Properties, function, and origin of the alveolar lining layer. Nature 1955;175(4469):1125-1126.
3. Pattle RE. Properties, function and origin of the alveolar lining layer. Proc R Soc (Lond) Ser B 1958;148(931):217-240.
4. Clements JA. Surface tension of lung extracts. Proc Soc Exp Biol Med 1957;95(1):170-172.
5. Notter RH. Lung surfactants: basic science and clinical applications. New York: Marcel Dekker; 2000.
6. Notter RH, Finkelstein JN. Pulmonary surfactant: an interdisciplinary approach. J Appl Physiol 1984;57(6):1613-1624.
7. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97(5 Pt 1):517-523.
8. Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A. Microaerosol administration of synthetic β,γ-dipalmitoyl-L-α-lecithin in the respiratory distress syndrome: a preliminary report. Can Med Assoc J 1964;90:55-57.
9. Chu J, Clements JA, Cotton EK, Klaus MH, Sweet AY, Thomas MA, et al. The pulmonary hypoperfusion syndrome. Pediatrics 1965; 35:733-742.
10. Chu J, Clements JA, Cotton EK, Klaus MH, Sweet AY, Tooley WH. Neonatal pulmonary ischemia. Clinical and physiologic studies. Pediatrics 1967;40(4):709-782.
11. Enhorning G, Grossman G, Robertson B. Pharyngeal deposition of surfactant in the premature rabbit fetus. Biol Neonate 1973;22:126-132.
12. Enhorning G, Grossman G, Robertson B. Tracheal deposition of surfactant before the first breath. Am Rev Respir Dis 1973;107(6): 921-927.
13. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1(8159):55-59.
14. AH. Pulmonary surfactant therapy. NEngl JMed 1993;328(12): 861-868.
15. Soll RF. Surfactant therapy in the USA: trials and current routines. Biol Neonate 1997;71(Suppl 1):1-7.
16. Willson DF, Chess PR, Notter RH. Surfactant for pediatric acute lung injury. Pediatr Clin N Am 2008;55(3):545-575.
17. Willson DF, Chess PR, Wang Z, Notter RH. Pulmonary surfactant: biology and therapy. In: Wheeler DA WH, Shanley TA, editors. Pediatric critical care medicine: basic science and clinical evidence. London: Springer-Verlag; 2007:453-466.
18. Raghavendran K, Pryhuber GS, Chess PR, BAD, Knight PR, Notter RH. Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem 2008;15(19):1911-1924.
19. Notter RH, Schwan AL, Wang Z, Waring AJ. Novel phospholipase- resistant lipid/peptide synthetic lung surfactants. Mini-Rev Med Chem 2007;7(9):932-944.
20. Walther FJ, Waring AJ, Sherman MA, Zasadzinski J, Gordon LM. Hydrophobic surfactant proteins and their analogues. Neonatology 2007;91(4):303-310.
21. Walther FJ, Waring AJ, Hernandez-Juviel JM, Gordon LM, Schwan AL, Jung CL, et al. Dynamic surface activity of a fully-synthetic phospholipase-resistant lipid/peptide lung surfactant. PLoS ONE 2007;2(10):e1039. DOI: 1010.1371/journal.pone.0001039.
22. Walther FJ, Waring AJ, Hernandez-Juviel JM, Gordon LM, Wang Z, Jung CL, et al. Critical structural and functional roles for the N-terminal insertion sequence in surfactant protein B analogs. PLoS ONE 2010;5(1):e8672. doi:8610.1371/journal.pone.0008672.
23. Wang Z, Chang Y, Schwan AL, Notter RH. Activity and inhibition resistance of a phospholipase-resistant synthetic exogenous surfactant in excised rat lungs. Am J Respir Cell Mol Biol 2007;37(4): 387-394.
24. Mingarro I, Lukovic D, Vilar M, Pérez-Gil J. Synthetic pulmonary surfactant preparations: new developments and future trends. Current Med Chem 2008;15(4):303-403.
25. Chess P, Finkelstein JN, Holm BA, Notter RH. Surfactant replacement therapy in lung injury. In: Notter RH, Finkelstein JN, Holm BA, editors. Lung injury: mechanisms, pathophysiology, and therapy. Boca Raton: Taylor & Francis; 2005:617-663.
26. Mizuno K, Ikegami M, Chen C-M, Ueda T, Jobe AH. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res 1995;37(3):271-276.
27. Seeger W, Grube C, Günther A, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993;6(7):971-977.
28. Hamvas A, Cole FS, deMello DE, Moxley M, Whitsett JA, Colten HR, et al. Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr 1994; 125(3):356-361.
29. Notter RH, Wang Z, Egan EA, Holm BA. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids 2002;114(1):21-34.
30. Curstedt T, Jornvall H, Robertson B, Bergman T, Berggren P. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur J Biochem 1987;168(2):255-262.
31. Oosterlaken-Dijksterhuis MA, Haagsman HP, van Golde LM, Demel RA. Characterization of lipid insertion into monomolecular layers mediated by lung surfactant proteins SP-B and SP-C. Biochemistry 1991;30(45):10965-10971.
32. Oosterlaken-Dijksterhuis MA, Haagsman HP, van Golde LM, Demel RA. Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C. Biochemistry 1991;30(33):8276-8281.
33. Oosterlaken-Dijksterhuis MA, van Eijk M, van Golde LMG, Haagsman HP. Lipid mixing is mediated by the hydrophobic surfactant protein SP-B but not by SP-C. Biochim Biophys Acta 1992;1110(1): 45-50.
34. Revak SD, Merritt TA, Degryse E, Stefani L, Courtney M, Hallman M, et al. The use of human low molecular weight (LMW) apoproteins in the reconstitution of surfactant biological activity. J Clin Invest 1988;81(3):826-833.
35. Seeger W, Günther A, Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants Am J Physiol 1992;261(3 Pt 1):L286-L291.
36. Wang Z, Gurel O, Baatz JE, Notter RH. Differential activity and lack of synergy of lung surfactant proteins SP-B and SP-C in surface- active interactions with phospholipids. J Lipid Res 1996;37(8): 1749-1760.
37. Yu SH, Possmayer F. Comparative studies on the biophysical activities of the low-molecular-weight hydrophobic proteins purified from bovine pulmonary surfactant. Biochim Biophys Acta 1988; 961(3):337-350.
38. Wang Z, Baatz JE, Holm BA, Notter RH. Content-dependent activity of lung surfactant protein B (SP-B) in mixtures with lipids. Am J Physiol 2002;283(5):L897-L906.
39. Walther FJ, Hernandez-Juviel J, Bruni R, Waring A. Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats. Am J Respir Crit Care Med 1997;156(3 Pt 1):855-861.
40. Clark JC, Weaver TE, Iwamoto HS, Ikegami M, Jobe AH, Hull WM, et al. Decreased lung compliance and air trapping in heterozygous SP-B-deficient mice. Am J Respir Cell Mol Biol 1997;16(1): 46-52.
41. Hamvas A, Nogee LM, deMello DE, Cole FS. Pathophysiology and treatment of surfactant protein-B deficiency. Biol Neonate 1995; 67(Suppl 1):18-31.
42. Hamvas A, Nogee LM, Mallory GB, Spray TL, Huddleston CB, August A, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr 1997;130(2):231-239.
43. Whitsett JA, Nogee LM, Weaver TE, Horowitz AD. Human surfactant protein B structure, function, regulation, and genetic disease. Physiol Rev 1995;75(4):749-757.
44. Ikegami M, Whitsett JA, Martis PC, Weaver TE. Reversibility of lung inflammation caused by SP-B deficiency. Am J Physiol Lung Cell Mol Physiol 2005;289(6):L962-L970.
45. Curstedt T, Johansson J. New synthetic surfactant: how and when? Biol Neonate 2006;89(4):336-339.
46. Turcotte JG, Sacco AM, Steim JM, Tabak SA, Notter RH. Chemical synthesis and surface properties of an analog of the pulmonary surfactant dipalmitoyl phosphatidylcholine analog. Biochim Biophys Acta 1977;488(2):235-248.
47. Turcotte JG, Lin WH, Pivarnik PE, Sacco AM, Bermel MS, Lu Z, et al. Chemical synthesis and surface activity of lung surfactant phospholipid analogs. II. Racemic N-substituted diether phosphonolipids. Biochim Biophys Acta 1991;1084(1):1-12.
48. Wang Z, Schwan AL, Lairson LL, O'Donnell JS, Byrne GF, Foye A, et al. Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine. Am J Physiol 2003;285(3):L550-L559.
49. Notter RH, Wang Z, Wang Z, Davy J, Schwan AL. Synthesis and surface activity of diether-linked phosphoglycerols: potential applications for exogenous lung surfactants. Bioorg Med Chem Lett 2007;17(1):113-117.
50. Chang Y, Wang Z, Schwan AL, Wang Z, Holm BA, Baatz JE, et al. Surface properties of sulfur- and ether-linked phosphonolipids with and without purified hydrophobic lung surfactant proteins. Chem Phys Lipids 2005;137(1-2):77-93.
51. Kim DK, Fukuda T, Thompson BT, Cockrill B, Hales C, Bonventre JV. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. AmJ Physiol 1995;269(1 Pt 1):L109-L118.
52. Touqui L, Arbibe L. A role for phospholipase A2 in ARDS pathogenesis. Molec Med Today 1999;5(6):244-249.
53. Vadas P. Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in Gram-negative septic shock. J Lab Clin Med 1984;104(6):873-881.
54. Vadas P, Pruzanski W. Role of secretory phospholipases A2 in the pathobiology of disease. Lab Invest 1986;55(4):391-404.
55. Ackerman SJ, Kwatia MA, Doyle CB, Enhorning G. Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma. Chest 2003;123(3 Suppl): 255S.
56. Attalah HL, Wu Y, Alaoui-El-Azher M, Thouron F, Koumanov K, Wolf C, et al. Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury. Eur Respir J 2003;21(6):1040-1045.
57. Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka ME. Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 2005;33(4):772-779.
58. Bose C, Corbet A, Bose G, Garcia-Prats J, Lombardy L, Wold D, et al. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr 1990;117(6):947-953.
59. Corbet A, Bucciarelli R, Goldman S, Mammel M, Wold D, Long W. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pediatr 1991;118(2):595-605.
60. Long W, Corbet A, Cotton R, Courtney S, McGuiness G, Walter D, et al. A controlled trial of synthetic surfactant in infants weighing 1,250 g or more with respiratory distress syndrome. N Engl J Med 1991;325(24):1696-1703.
61. Long W, Thompson R, Sundell H, Schumacher R, Volberg F, Guthrie R. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700 to 1350 gram infants with respiratory distress syndrome. J Pediatr 1991;11(4 Pt 1):595-605.
62. Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ, et al. A multicenter randomized masked comparison of natural vs synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996;128(3):396-406.
63. Hudak ML, Martin DJ, Egan EA, Matteson EJ, Cummings J, Jung AL, et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 1997; 100(1):39-50.
64. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, et al. Aerosolized surfactant in adults with sepsis- induced acute respiratory distress syndrome. N Engl J Med 1996;334(22):1417-1421.
65. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmere WJ, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155(4):109-131.
66. Khammash H, Perlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993;92(1):135-139.
67. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996;97(1):48-52.
68. Lotze A, Knight GR, Martin GR, Bulas DI, Hull WM, O'Donnell RM, et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 1993;122(2):261-268.
69. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 1998;132(1): 40-47.
70. Jobe AH, Ikegami M. Surfactant and acute lung injury. Proc Assoc Am Physiol 1998;110(6):489-495.
71. Notter RH, Wang Z. Pulmonary surfactant: physical chemistry, physiology and replacement. Rev Chem Eng 1997;13:1-118.
72. Wang Z, Holm BA, Matalon S, Notter RH. Surfactant activity and dysfunction in lung injury. In: Notter RH, Finkelstein JN, Holm BA, editors. Lung injury: mechanisms, pathophysiology, and therapy. Boca Raton: Taylor & Francis; 2005;297-352.
73. Holm BA, Notter RH, Finkelstein JH. Surface property changes from interactions of albumin with natural lung surfactant and extracted lung lipids. Chem Phys Lipids 1985;38(3):287-298.
74. Seeger W, Stöhr G, Wolf HR, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 1985;58(2):326-338.
75. Holm BA, Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol 1987;63(4): 1434-1442.
76. Holm BA, Enhorning G, Notter RH. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem Phys Lipids 1988;49(1-2):49-55.
77. Fuchimukai T, Fujiwara T, Takahashi A, Enhorning G. Artificial pulmonary surfactant inhibited by proteins. J Appl Physiol 1987; 62(2):429-437.
78. Keough KWM, Parsons CS, Tweeddale MG. Interactions between plasma proteins and pulmonary surfactant: pulsating bubble studies. Can J Physiol Pharmacol 1989;67(6):663-668.
79. Wang Z, Notter RH. Additivity of protein and non-protein inhibitors of lung surfactant activity. Am J Respir Crit Care Med 1998; 158(1):28-35.
80. Hall SB, Hyde RW, Notter RH. Changes in subphase surfactant aggregates in rabbits injured by free fatty acid. Am J Respir Crit Care Med 1994;149(5):1099-1106.
81. Hall SB, Lu ZR, Venkitaraman AR, Hyde RW, Notter RH. Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics. J Appl Physiol 1992;72:1708-1716.
82. Hall SB, Notter RH, Smith RJ, Hyde RW. Altered function of pulmonary surfactant in fatty acid lung injury. J Appl Physiol 1990; 69(3):1143-1149.
83. Holm BA, Wang Z, Notter RH. Multiple mechanisms of lung surfactant inhibition. Pediatr Res 1999;46(1):85-93.
84. Seeger W, Lepper H, Hellmut RD, Neuhof H. Alteration of alveolar surfactant function after exposure to oxidant stress and to oxygenated and native arachadonic acid in vitro. Biochim Biophys Acta 1985;835(1):58-67.
85. Davidson BA, Knight PR, Wang Z, Chess PR, Holm BA, Russo TA, et al. Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates. Am J Physiol Lung Cell Mol Physiol 2005;288(4):L699-L708.
86. Russo TA, Bartholomew LA, Davidson BA, Helinski JD, Carlino UB, Knight PR, et al. Total extracellular surfactant is increased but abnormal in a rat model of Gram-negative bacterial pneumonitis. Am J Physiol 2002;283(3):L655-L663.
87. Russo TA, Wang Z, Davidson BA, Genagon SA, Beanan JM, Olsen R, et al. Surfactant dysfunction and lung injury due to the E. coli virulence factor hemolysin in a rat pneumonia model. Am J Physiol Lung Cell Mol Physiol 2007;292(3):L632-L643.
88. Wright TW, Notter RH, Wang Z, Harmsen AG, Gigliotti F. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 2001;69(2):758-764.
89. Hickman-Davis J, Wang Z, Chess PR, Page GP, Matalon S, Notter RH. Surfactant dysfunction in SP-A-deficient and iNOS-deficient mice with mycoplasma infection. Am J Respir Cell Mol Biol 2007; 36(1):103-113.
90. Raghavendran K, Davidson BA, Knight PR, Wang Z, Helinski J, Chess PR, et al. Surfactant dysfunction in lung contusion with and without superimposed gastric aspiration in a rat model. Shock 2008; 30(5):508-517.
91. Lewis JF, Ikegami M, Jobe AH. Altered surfactant function and metabolism in rabbits with acute lung injury. J Appl Physiol 1990; 69(6):2303-2310.
92. Günther A, Siebert C, Schmidt R, Ziegle S, Grimminger F, Yabut M, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153(1):176-184.
93. Veldhuizen RAW, McCaig LA, Akino T, Lewis JF. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995;152(6 Pt 1):1867-1871.
94. Cockshutt A, Possmayer F. Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by plasma proteins. Biochim Biophys Acta 1991;1086(1):63-71.
95. Wang Z, Schwab U, Rhoades E, Chess PR, Russell DG, Notter RH. Peripheral cell wall lipids of mycobacterium tuberculosis are inhibitory to surfactant function. Tuberculosis (Ednib) 2008;88(3): 178-186.
96. Wang Z, Foye A, Chang Y, Chess PR, Wright TW, Bhagwat S, et al. Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro. Am J Physiol Lung Cell Mol Physiol 2005;288(6):L1124-L1131.
97. Moses D, Holm BA, Spitale P, Liu M, Enhorning G. Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 1991;164(2):477-481.
98. Pison U, Tam EK, Caughey GH, Hawgood S. Proteolytic inactivation of dog lung surfactant-associated proteins by neutrophil elastase. Biochim Biophys Acta 1989;992(3):251-257.
99. Holm BA, Kelcher L, Liu M, Sokolowski J, Enhorning G. Inhibition of pulmonary surfactant by phospholipases. J Appl Physiol 1991;71(1):317-321.
100. Enhorning G, Shumel B, Keicher L, Sokolowski J, Holm BA. Phospholipases introduced into the hypophase affect the surfactant film outlining a bubble. J Appl Physiol 1992;73(3):941-945.
101. Hickman-Davis JM, Fang FC, Nathan C, Shepherd VL, Voelker DR, Wright JR. Lung surfactant and reactive oxygen-nitrogen species: antimicrobial activity and host-pathogen interactions. Am J Physiol 2001;281(3):L517-L523.
102. Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol 1993;265(6 Pt 1):L555-L564.
103. Amirkhanian JD, Merritt TA. Inhibitory effects of oxyradicals on surfactant function: utilizing in vitro Fenton reaction. Lung 1998; 176(1):63-72.
104. Finkelstein JN. Physiologic and toxicologic response of alveolar type II cells. Toxicology 1990;60(1-2):41-52.
105. Finkelstein JN, Horowitz S, Sinkin RA, Ryan RM. Cellular and molecular responses to lung injury in relation to induction of tissue repair and fibrosis. Clinics in Perinatology 1992;19(3):603-620.
106. Mason RJ, Dobbs LG, Greenleaf RD, Williams MC. Alveolar type II cells. Fed Proc 1977;36:2697-2702.
107. Mason RJ, Williams MC. Alveolar type II cells. In: Crystal R, West JB, Weibel ER, Barnes, PJ, editors. The lung: scientific foundations. Philadelphia: Lipincott-Raven; 1997:235-246.
108. Seeger W, Pison U, Buchhorn R, Obestacke U, Joka T. Surfactant abnormalities and adult respiratory failure. Lung 1990;168(Suppl): 891-902.
109. Pison U, Seeger W, Buchhorn R, Joka T, Brand M, Obertacke U, et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989;140(4):1033-1039.
110. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88(6):1976-1981.
111. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999;13(6):1455-1476.
112. Schmidt R, Markart P, Ruppert C, Wygrecka M, Kuchenbuch T, Walmrath D, et al. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res 2007;8:55.
113. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999;160(6):1843-1850.
114. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149(3 Pt 1):818-824.
115. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342(18):1334-1348.
116. Knight PR, Rotta AT. Acute lung injury: etiologies and basic features. In: Notter RH, Finkelstein JN, Holm BA, editors. Lung injury: mechanisms, pathophysiology, and therapy. Boca Raton: Taylor & Francis; 2005:67-110.
117. Artigas A, Bernard GR, Carlet J, Dreyfuss D, Gattinoni L, Hudson L, et al. The American-European consensus conference on ARDS. Part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling. Intensive Care Med 1998;24(4):378-398.
118. Krafft P, Fridrich P, Pernerstorfer T, Fitzgerald RD, Koc D, Schneider B, et al. The acute respiratory distress syndrome; definitions, severity, and clinical outcome. An analysis of 101 clinical investigations Intensive Care Med 1996;22(6):519-529.
119. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353(16):1685-1693.
120. DeBruin W, Notterman DA, Magid M, Godwin T, Johnston S. Acute hypoxemic respiratory failure in infants and children: clinical and pathologic characteristics. Crit Care Med 1992;20(9):1223-1234.
121. Flori HR, Glidden DV, Rutherford GW, Matthay MA. Pediatric acute lung injury. Prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med 2005;171(9):995-1001.
122. Dos Santos C, Slutsky A. Invited review: mechanisms of ventilatory induced lung injury: a perspective. J Appl Physiol 2000;89(4): 1645-1655.
123. Ricard J, Dreyfuss D, Saumon G. Production of inflammatory cytokines in ventilator induced lung injury: a reappraisal. Am J Respir Crit Care Med 2001;163(5):1176-1180.
124. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342(18):1301-1308.
125. Pelosi P, Negrini D. Extracellular matrix and mechanical ventilation in healthy lungs: back to baro/volotrauma?. Curr Opin Crit Care 2008;14(1):16-21.
126. Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003;167(11):1562-1566.
127. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004;351(9):884-892.
128. Lachmann B, Fujiwara T, Chida S, Morita T, Konishi M, Nakamura K, et al. Surfactant replacement therapy in experimental adult respiratory distress syndrome (ARDS). In: Cosmi EV, Scarpelli EM, editors. Pulmonary surfactant system. Amsterdam: Elsevier; 1983: 221-235.
129. Kobayashi T, Kataoka H, Ueda T, Murakami S, Takada Y, Kobuko M. Effect of surfactant supplementation and end expiratory pressure in lung-lavaged rabbits. J Appl Physiol 1984;57(4):995-1001.
130. Berggren P, Lachmann B, Curstedt T, Grossmann G, Robertson B. Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress induced by repeated lung lavage. Acta Anaesthesiol Scand 1986;30(4):321-328.
131. Lewis JF, Goffin J, Yue P, McCaig LA, Bjarneson D, Veldhuizen RAW. Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury. J Appl Physiol 1996;80(4):1156-1164.
132. Walther F, Hernandez-Juviel J, Bruni R, Waring AJ. Protein composition of synthetic surfactant affects gas exchange in surfactantdeficient rats. Pediatr Res 1998;43(5):666-673.
133. Walther FJ, Hernandez-Juviel JM, Mercado PE, Gordon LM, Waring AJ. Surfactant with SP-B and SP-C analogs improves lung function in surfactant deficient rats. Biol Neonate 2002;82(3):181-187.
134. Gupta M, Hernandez-Juviel JM, Waring AJ, Bruni R, Walther FJ. Comparison of functional efficacy of surfactant protein B analogues in lavaged rats. Eur Respir J 2000;16(6):1129-1133.
135. Ruppert C, Kuchenbuch T, Boensch M, Schmidt S, Mathes U, Hillebrand V, et al. Dry powder aerosolization of a recombinant surfactant protein-C-based surfactant for inhalative treatment of the acutely inflamed lung. Crit Care Med 2010;38(7):1584-1591.
136. Krause M, Olsson T, Law AB, Parker RA, Lindstrom DP, Sundell HW, et al. Effect of volume recruitment on response to surfactant treatment in rabbits with lung Injury. Am J Respir Crit Care Med 1997;156(3 Pt 1):862-866.
137. Krause MF, Jäkel C, Haberstroh J, Schulte-Mönting J, Leititis JU, Orlowska-Volk M. Alveolar recruitment promotes homogeneous surfactant distribution in a piglet model of lung injury. Pediatr Res 2001;50(1):34-43.
138. van Daal GJ, Eijking EP, So KL, Fievez RB, Sprenger MJW, van Dam DW, et al. Acute respiratory failure during pneumonia indeced by Sendai virus. Adv Exp Med Biol 1992;316:319-326.
139. van Daal GJ, Bos JAH, Eijking EP, Gommers D, Hannappel E, Lachmann B. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis 1992;145(4 Pt 1):859-863.
140. Eijking EP, van Daal GJ, Tenbrinck R, Luyenduijk A, Sluiters JF, Hannappel E, et al. Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med 1990;17:475-478.
141. Sherman MP, Campbell LA, Merritt TA, Long WA, Gunkel JH, Curstedt T, et al. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits. J Pediatr 1994;125(6 Pt 1):939-947.
142. Kobayashi T, Ganzuka M, Taniguchi J, Nitta K, Murakami S. Lung lavage and surfactant replacement for hydrochloric acid aspiration in rabbits. Acta Anaesthesiol Scand 1990;34(3):216-221.
143. Zucker A, Holm BA, Wood LDH, Crawford G, Ridge K, Sznajder IA. Exogenous surfactant with PEEP reduces pulmonary edema and improves lung function in canine aspiration pneumonitis. J Appl Physiol 1992;73:679-686.
144. Schlag G, Strohmaier W. Experimental aspiration trauma: comparison of steroid treatment versus exogenous natural surfactant. Exp Lung Res 1993;19:397-405.
145. Eijking EP, Gommers D, So KL, Vergeer M, Lachmann B. Surfactant treatment of respiratory failure induced by hydrochloric acid aspiration in rats. Anesthesiology 1993;78:1145-1151.
146. Tashiro K, Li W-Z, Yamada K, Matsumoto Y, Kobayashi T. Surfactant replacement reverses respiratory failure induced by intratracheal endotoxin in rats. Crit Care Med 1995;23(1):149-156.
147. Tashiro K, Yamada K, Li WZ, Matsumoto Y, Kobayashi T. Aerosolized and instilled surfactant therapies for acute lung injury caused by intratracheal endotoxin in rats. Crit Care Med 1996;24(3):488-494.
148. Matalon S, Holm BA, Loewen GM, Baker RR, Notter RH. Sublethal hyperoxic injury to the alveolar epithelium and the pulmonary surfactant system. Exp Lung Res 1988;14(Suppl):1021-1033.
149. Matalon S, Holm BA, Notter RH. Mitigation of pulmonary hyperoxic injury by administration of exogenous surfactant. J Appl Physiol 1987;62(2):756-761.
150. Zhu GF, Sun B, Niu S, Cai YY, Lin K, Lindwall R, et al. Combined surfactant therapy and inhaled nitric oxide in rabbits with oleic acid-induced acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;158(2):437-443.
151. Bellman G. Pathogenesis of oleic acid-induced lung injury in the rat: distribution of oleic acid during injury and early endothelial cell changes. Lipids 1995;39:817-823.
152. Nieman G, Gatto L, Paskanik A, Yang B, Fluck R, Picone A. Surfactant replacement in the treatment of sepsis-induced adult respiratory distress syndrome in pigs. Crit Care Med 1996;24(6): 1025-1033.
153. Lutz C, Carney D, Finck C, Picone A, Gatto L, Paskanik A, et al. Aerosolized surfactant improves pulmonary function in endotoxininduced lung injury. Am J Respir Crit Care Med 1998;158(3):840-845.
154. Willson DF, Thomas NJ, Markovitz BP, DiCarlo JV, Pon S, Jacobs BR, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005;293(4): 470-476. Erratum in: JAMA 2005;294(8):900.
155. Lewis J, Ikegami M, Higuchi R, Jobe A, Absolom D. Nebulized vs. instilled exogenous surfactant in an adult lung injury model. J Appl Physiol 1991;71(4):1270-1276.
156. Lewis J, Ikegami M, Tabor B, Jobe A. Aerosolized surfactant is preferentially deposited in normal versus injured regions of the lung in a heterogeneous lung injury model (abstract). Am Rev Respir Dis 1992;145:A184.
157. Lewis J, Veldhuizen RAW. Surfactant - current and potential therapeutic application in infants and adults. J Aerosol Med 1996;9(1): 143-154.
158. Lewis JF, Ikegami M, Jobe AH, Absolom D. Physiologic responses and distribution of aerosolized surfactant (Survanta) in a non-uniform model of lung injury. Am Rev Respir Dis 1993;147(6 Pt 1):1364-1370.
159. Lewis JF, Ikegami M, Jobe AH, Tabor H. Aerosolized surfactant treatment of preterm lambs. J Appl Physiol 1991;70(2):869-876.
160. Schermuly R, Schmehl T, Günther A, Grimminger F, Seeger W, Walmrath D. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury: impact on gas exchange. Am J Respir Crit Care Med 1997;156(2 Pt 1):445-453.
161. Schermuly RT, Günther A, Weissmann N, Ghofrani HA, Seeger W, Grimminger F, et al. Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion mismatch in a model of acute lung injury. Am J Respir Crit Care Med 2000;161(1):152-159.
162. Ellyett KM, Broadbent RS, Fawcett ER, Campbell AJ. Surfactant aerosol treatment of respiratory distress syndrome in the spontaneously breathing premature rabbit. Pediatr Res 1996;39(6):953-957.
163. Dijk PH, Heikamp A, Oetomo SB. Surfactant nebulization versus Instillation during high frequency ventilation in surfactant-deficient rabbits. Pediatr Res 1998;44(5):699-704.
164. Wagner MH, Wiethoff S, Friedrich W, Mollenhauer I, Obladen M, Boenick U. Ultrasonic surfactant nebulization with different exciting frequencies. Biphysical Chem 2000;84(1):35-43.
165. Bahlmann H, Sun B, Nilsson G, Curstedt T, Robertson B. Aerosolized surfactant in lung-lavaged adult rats: factors influencing the therapeutic response. Acta Anaesthesiol Scand 2000;44(5):612-622.
166. Huang Y-CT, Caminiti SP, Fawcett TA, Moon RE, Fracica PJ, Miller FJ, et al. Natural surfactant and hyperoxic lung injury in primates. I. Physiology and biochemistry. J Appl Physiol 1994; 76(3):991-1001.
167. Fok TF, Al-Essa M, Dolovich M, Rasid F, Kirpalani H. Nebulisation of surfactants in an animal model of neonatal respiratory distress. Arch Dis Child Fetal Neonatal Ed 1998;78(1):F3-F9.
168. Lewis JF, Tabor B, Ikegami M, Jobe AH, Joseph M, Absolom D. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs nebulized surfactant. J Appl Physiol 1993;74(3): 1256-1264.
169. Jorch G, Hartl H, Roth B, Kribs A, Gortner L, Schaible T, et al. Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonology 1997;24(3):222-224.
170. Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Liu G. A multicenter pilot study of Aerosurf™ delivered via nasal continuous positive airway pressure (nCPAP) to prevent respiratory distress syndrome in preterm neonates. Pediatr Res 2006;59.
171. Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, Robertson B, et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Pædiatr 2000;89(4): 460-464.
172. Arroe M, Pedersen-Bjergaard L, Albertsen P, Bode S, Greisen G. Inhalation of aerosolized surfactant (Exosurf) to neonates treated with continuous positive airway pressure. Prenat Neonat Med 1998; 3:346-352.
173. Shah S. Exogenous surfactant: intubated present, nebulized future? World J Pediatr 2011;7(1):11-15.
174. Marks LB, Notter RH, Oberdoerster G, McBride JT. Ultrasonic and jet aerosolization of phospholipids and the effects on surface activity. Pediatr Res 1984;17:742-747.
175. Marks LB, Oberdoerster G, Notter RH. Generation and characterization of aerosols of dispersed surface active phospholipids by ultrasonic and jet nebulization. J Aerosol Sci 1983;14:683-694.
176. Bjorklund LJ, Ingimarsson J, Curstedt T, Joseph J, Robertson B, Werner O, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997;42(1-3):348-355.
177. Hillman NH, Moss TJM, Kallapur SG, Bachurski J, Pillow J, Polglase GR, et al. Brief, large tidal volume ventilation initiates lung injury and a systemic response in fetal sheep. Am J Respir Crit Care Med 2007;176(6):575-581.
178. Nilsson R, Grossman G, Robertson B. Bronchiolar epithelial lesions induced in the premature rabbit neonate by short periods of artificial ventilation. Acta Pathol Microbiol Scand 1980;88:359-367.
179. Seidner SR, Ikegami M, Yamada T, Ryder ED, Castro R, Jobe AH. Decreased surfactant dose-response after delayed administration to preterm rabbits. Am J Respir Crit Care Med 1995;152(1):113-120.
180. Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks gestation. N Engl J Med 1991;324(13):865-871.
181. Kattwinkel J, Bloom B, Delmore P, Davis C, Farrell E, Friss H, et al. Prophylactic administration of calf lung surfactant extract (CLSE) is more effective than early treatment of RDS in 29-32 weeks gestation babies. Pediatrics 1993;92(1):90-98.
182. van Der Beek J, Plotz F, van Overbeek F, Heikamp A, Beekhuis H, Wildevuur C, et al. Distribution of exogenous surfactant in rabbits with severe respiratory failure: the effect of volume. Pediatr Res 1993;34(2):154-158.
183. Segerer H, van Gelder W, Angenent FW, van Woerkens LJ, Curstedt T, Obladen M, et al. Pulmonary distribution and efficacy of exogenous surfactant in lung-lavaged rabbits are influenced by the instillation technique. Pediatr Res 1993;34(4):490-494.
184. Hartog A, Gommers D, Haitsma JJ, Lachmann B. Improvement of lung mechanics by exogenous surfactant: effect of prior application of high positive end-expiratory pressure. Br J Anaesth 2000;85(5): 752-756.
185. Kesecioglu J, Beale R, Stewart TE, Findlay GP, Rouby J-J, Holzapfel L, et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2009;180(10):989-994.
186. Günther A, Schmidt R, Harodt J, Schmehl T, Walmrath D, Ruppert C, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J 2002;19(5):797-804.
187. Walmrath D, Gunther A, Ghofrani HA, Schermuly R, Schnedier T, Grimminger F, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996;154(1):57-62.
188. Walmrath D, Grimminger F, Pappert D, Knothe C, Obertacke U, Benzing A, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J 2002;19(5):805-810.
189. Spragg R, Gilliard N, Richman P, Smith R, Hite R, Pappert D, et al. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994;105(1):195-202.
190. Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, et al. Bronchopulmonary segmental lavage with Surfaxin (KL(4)- surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999;160(4):1188-1195.
191. Willson DF, Jiao JH, Bauman LA, Zaritsky A, Craft H, Dockery K, et al. Calf lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 1996;24(8):1316-1322.
192. Willson DF, Bauman LA, Zaritsky A, Dockery K, James RL, Stat M, et al. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit Care Med 1999;27(1):188-195.
193. López-Herce J, de Lucas N, Carrillo A, Bustinza A, Moral R. Surfactant treatment for acute respiratory distress syndrome. Arch Dis Child 1999;80(3):248-252.
194. Hermon MM, Golej J, Burda H, Boigner H, Stoll E, Vergesslich K, et al. Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit. Shock 2002;17(4):247-251.
195. Herting E, Moller O, Schiffman JH, Robertson B. Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr 2002;91(11): 1174-1178.
196. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991;87(1):101-107.
197. Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiol Scand 1998;42(7):805-810.
198. Luchetti M, Ferrero F, Gallini C, Natale A, Pigna A, Tortorolo L, et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr Crit Care Med 2002;3(3):261-268.
199. Moller JC, Schaible T, Roll C, Schiffmann JH, Bindl L, Schrod L, et al. Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study. Intensive Care Med 2003;29(3):437-446.
200. Amital A, Shitrit D, Raviv Y, Saute M, Medalion B, Bakai L, et al. The use of surfactant in lung transplantation. Transplantation 2008; 86(11):1554-1559.
201. Kermeen FD, McNeil KD, Fraser JF, McCarthy J, Ziegenfuss MD, Mullarny D, et al. Resolution of severe ischemia-reperfusion injury post-lung transplantation after administration of endobronchial surfactant. J Heart Lung Transplant 2007;26(8):850-856.
202. Della Rocca G, Pierconti F, Costa MG, Coccia C, Pompei L, Rocco M, et al. Severe reperfusion lung injury after double lung transplantation. Crit Care 2002;6(3):240-244.
203. Strüber M, Fischer S, Niedermeyer J, Warnecke G, Gohrbandt B, Gorler A, et al. Effects of exogenous surfactant instillation in clinical lung transplantation: a prospective, randomized trial. J Thorac Cardiovasc Surg 2007;133(6):1620-1625.
204. Strüber M, Hirt SW, Cremer J, Harringer W, Haverich A. Surfactant replacement in reperfusion injury after clinical lung transplantation. Intensive Care Med 1999;25(8):862-864.
205. Varisco BM, Palmatier CM, Alten JA. Reversal of intractable hypoxemia with exogenous surfactant (calfactant) facilitating complete neurological recovery in a pediatric drowning victim. Pediatr Emerg Care 2010;26(8):571-573.
206. Holopainen R, Aho H, Laine J, Peuravuori H, Soukka H, Kääpä P. Human meconium has high phospholipase A2 activity and induces cellular injury and apoptosis in piglet lungs. Pediatr Res 1999; 46(5):626-632.
207. Clark DA, Nieman GF, Thompson JE, Paskanik AM, Rokhar JE, Bredenberg CE. Surfactant displacement by meconium free fatty acids: an alternative explanation for atelectasis in meconium aspiration syndrome. J Pediatr 1987;110(5):765-770.
208. Notter RH, Finkelstein JN, Holm BA. Lung injury: mechanisms, pathophysiology and therapy. Boca Raton: Taylor & Francis; 2005.
209. Caironi P, Langer T, Gattinoni L. Acute lung injury/acute respiratory distress syndrome pathophysiology: what we have learned from computed tomography scanning. Curr Opin Crit Care 2008;14(1): 64-69.
210. Gattinoni L, Bombino M, Pelosi P, Lissoni A, Pesente A, Fumagalli R, et al. Lung structure and function in different stages of severe adult respiratory distress syndrome. JAMA 1994;271(22):1772-1779.
211. Gattinoni L, Pesenti A. The concept of the "baby lung". Intensive Care Med 2005;31(6):776-784.
212. Pryhuber GS, D'Angio CT, Finkelstein JN, Notter RH. Combinedmodality therapies for lung injury. In: Notter RH, Finkelstein JN, Holm BA, editors. Lung injury: mechanisms, pathophysiology, and therapy. Boca Raton: Taylor & Francis; 2005:779-838.